24 Apr 2021 With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick, simple ways to screen patients and determine if they have amyloid plaque in their brains. The current gold-standard diagnostics used in research—amyloid PET scans and cerebrospinal fluid biomarkers—are expensive, invasive, or not readily available to many patients. With that in mind, the Global Alzheimer’s Platform has launched Bio-Hermes, a collaborative study with 10 different technology companies that will assess how accurately low-cost, rapid blood-based, and digital biomarker tests detect amyloid accumulation and cognitive decline. Bio-Hermes study will assess digital and blood-based biomarkers.